Search

Your search keyword '"Yang, Yi‐Tsung"' showing total 8 results
Start Over Author "Yang, Yi‐Tsung" Search Limiters Peer Reviewed
8 results on '"Yang, Yi‐Tsung"'

1. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms

Author

Lee, Wan-Hsuan, Lin, Chien-Chin, Tsai, Cheng-Hong, Tien, Feng-Ming, Lo, Min-Yen, Tseng, Mei-Hsuan, Kuo, Yuan-Yeh, Yu, Shan-Chi, Liu, Ming-Chih, Yuan, Chang-Tsu, Yang, Yi-Tsung, Chuang, Ming-Kai, Ko, Bor-Sheng, Tang, Jih-Luh, Sun, Hsun-I, Chuang, Yi-Kuang, Tien, Hwei-Fang, Hou, Hsin-An, and Chou, Wen-Chien

Published
2024
Full Text
View/download PDF

2. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification

Author

Lee, Wan-Hsuan, Tsai, Ming-Tao, Tsai, Cheng-Hong, Tien, Feng-Ming, Lo, Min-Yen, Tseng, Mei-Hsuan, Kuo, Yuan-Yeh, Liu, Ming-Chih, Yang, Yi-Tsung, Chen, Jui-Che, Tang, Jih-Luh, Sun, Hsun-I, Chuang, Yi-Kuang, Lin, Liang-In, Chou, Wen-Chien, Lin, Chien-Chin, Hou, Hsin-An, and Tien, Hwei-Fang

Published
2023
Full Text
View/download PDF

4. Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.

Author

Yang, Yi‐Tsung, Yao, Chi‐Yuan, Kao, Chein‐Jun, Chiu, Po‐Ju, Lin, Ming‐En, Hou, Hsin‐An, Lin, Chien‐Chin, Chou, Wen‐Chien, and Tien, Hwei‐Fang

Subjects
*ACUTE myeloid leukemia, *ALTERNATIVE RNA splicing, *HEMATOPOIETIC stem cells, *TRANSCRIPTION factors, *RNA sequencing
Abstract

Summary: Aberrant alternative splicing (AS) contributes to leukemogenesis, but reports on the clinical and biological implications of aberrant AS in acute myeloid leukaemia (AML) remain limited. Here, we used RNA‐seq to analyse AS in AML cells from 341 patients, comparing them to healthy CD34+ haematopoietic stem cells (HSCs). Our findings highlight distinct AS patterns in the nuclear transcription factor Y subunit alpha (NFYA) gene, with two main isoforms: NFYA‐L (Long) and NFYA‐S (Short), differing in exon 3 inclusion. Patients with lower NFYA‐L but higher NFYA‐S expression, termed NFYA‐S predominance, displayed more favourable characteristics and better outcomes following intensive chemotherapy, regardless of age and European LeukemiaNet risk classification, compared to those with higher NFYA‐L but lower NFYA‐S expression, termed NFYA‐L predominance. The prognostic effects were validated using The Cancer Genome Atlas cohort. Transcriptome analysis revealed upregulated cell cycle genes in NFYA‐S predominant cases, resembling those of active HSCs, demonstrating relative chemosensitivity. Conversely, NFYA‐L predominant cases, as observed in KMT2A‐rearranged leukaemia, were associated with relative chemoresistance. NFYA‐S overexpression in OCI‐AML3 cells promoted cell proliferation, S‐phase entry and increased cytarabine sensitivity, suggesting its clinical and therapeutic relevance in AML. Our study underscores NFYA AS as a potential prognostic biomarker in AML. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients

Author

Yang, Yi-Tsung, Hou, Hsin-An, Liu, Chieh-Yu, Lin, Chien-Chin, Chou, Wen-Chien, Lee, Fen-Yu, Liu, Ming-Chih, Liu, Chia-Wen, Tang, Jih-Luh, Yao, Ming, Li, Chi-Cheng, Kuo, Yuan-Yeh, Huang, Shang-Yi, Ko, Bor-Sheng, Chen, Chien-Yuan, Hsu, Szu-Chun, Lin, Chien-Ting, Wu, Shang-Ju, Tsay, Woei, Chen, Yao-Chang, and Tien, Hwei-Fang

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results